Table 2.
Clinical details, disease outcomes, and CTC results in subjects who experienced recurrent disease
| Subject # | Previous history of NSCLC | Tumor size (cm) | Histology | Pre-RT SUVmax | Post-RT SUVmax | Total dose (Gy) / fractions | Biological Equivalent Dose (Gy) | Local recurrence | Nodal recurrence | Distant recurrence | Vital status | Total follow-up | Pre-RT CTC counta | Max. CTC count within 3 mo. post-RTb | Time of first positive CTC test in follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 | No | 1.6 | None | 4.5 | 2.1 | 5000/4 | 112.5 | 28.2 mo. | - | - | Alive | 37.4 mo. | 4.0 | 1.1 | 26.8 mo. |
| 97 | No | 2.1 | None | 2.5 | 5.4 | 5000/4 | 112.5 | 33.3 mo. | - | - | Alive | 33.8 mo. | 0.4 | 2.0 | 2.9 mo. |
| 26 | No | 1.8 | Adenocarcinoma | 3.3 | 3.6 | 5000/5 | 100 | 52.0 mo. | - | - | Alive | 54.4 mo. | 54.2 | 0.5 | 10.5 mo. |
| 136 | Yes | 3.7 | Squamous cell | 9.6 | 10 | 5000/5 | 100 | 6.3 mo. | 6.3 mo. | - | Deceased | 18.8 mo. | 1.5 | - | - |
| 6 | Yes | 1.7 | Adenocarcinoma | 5.1 | 0.8 | 5000/5 | 100 | - | 7.0 mo. | - | Deceased | 12.8 mo. | 0.4 | 2.8 | 1.3 mo. |
| 168 | No | 4.7 | Squamous cell | 19.1 | - | 6000/15 | 84 | 13.2 mo. | 13.2 mo. | - | Deceased | 14.9 mo. | 0.1 | 11.6 | 3 mo. |
| 33 | Yes | 1.2 | None | 0.8 | - | 5000/5 | 100 | 37.0 mo. | 37.0 mo. | - | Alive | 41.9 mo. | 70.1 | 51.6 | 2.9 mo. |
| 143 | No | 3.6 | Squamous cell | 19.1 | 0.8 | 5000/5 | 100 | 5.2 mo. | 8.9 mo. | 3.2 mo. | Alive | 24.3 mo. | 0.2 | 0.1 | - |
| 147 | No | 3 | Adenocarcinoma | 11.5 | 0.8 | 5000/4 | 112.5 | - | 21.7 mo. | 9.4 mo. | Alive | 24.8 mo. | 0 | 14.3 | 3.3 mo. |
| 94 | No | 3 | Adenocarcinoma | 7.8 | 0.8 | 5400/11 | 80.5 | 13.7 mo. | 13.7 mo. | 11.4 mo. | Deceased | 13.8 mo. | 6.8 | 10.8 | 0.6 mo. |
| 142 | No | 3.5 | Adenocarcinoma | 17.2 | - | 6000/15 | 84 | 15.9 mo. | 15.9 mo. | 14.5 mo. | Deceased | 21.5 mo. | 0 | 1.7 | 3.5 mo. |
| 71 | No | 2.3 | Adenocarcinoma | 5.4 | 5.2 | 5000/4 | 112.5 | 6.2 mo. | 6.2 mo. | 15.3 mo. | Deceased | 21.3 mo. | 0 | 0.1 | - |
| 20 | No | 3 | None | 9.6 | 2.8 | 5000/5 | 100 | 29.6 mo. | 29.6 mo. | 17.2 mo. | Deceased | 37.8 mo. | 22.9 | 1.5 | 1 mo. |
| 62 | No | 1.8 | None | 7.2 | 7.4 | 5000/4 | 112.5 | 20.7 mo. | 20.7 mo. | 20.7 mo. | Deceased | 35.9 mo. | 0 | 0.1 | - |
| 84 | No | 1.3 | Adenocarcinoma | 3.9 | 1.4 | 5000/5 | 100 | - | - | 22.6 mo. | Alive | 46.5 mo. | 8.8 | 20.0 | 0.9 mo. |
| 126 | No | 1.6 | None | 3.6 | 1.6 | 5000/4 | 112.5 | 7.8 mo. | - | 24.0 mo. | Alive | 25.1 mo. | 0.5 | 0.1 | - |
| 50 | Yes | 3.2 | None | 3.1 | 5.4 | 5000/4 | 112.5 | - | - | 28.1 mo. | Alive | 43.3 mo. | 2.9 | 0.2 | - |
| 11 | Yes | 2 | None | 12.7 | 5.4 | 5000/5 | 100 | 32.8 mo. | 19.9 mo. | 32.8 mo. | Deceased | 32.8 mo. | 5.2 | 5.9 | 3.1 mo. |
| 25 | No | 1.6 | None | 1.7 | 0.8 | 5000/5 | 100 | - | 44.2 mo. | 44.2 mo. | Alive | 50.3 mo. | 6.0 | 0.1 | 9.9 mo. |
a
bold, black=CTC unfavorable (CTC>=5)
b
bold, red=CTC positive (CTC>=1.3)